Appendix Cancer Clinical Trials and Research
Appendiceal Cancer Research, International Listing of Appendix Cancer Research Specialists
"Today's cancer research brings tomorrow's cures!©"
Join the PMP Pals' Network! Help us to help others!
New research studies and clinical trials for the treatment of Appendix Cancer, Colorectal Cancers, Pseudomyxoma Peritonei, Peritoneal Carcinomatosis and Peritoneal Surface Malignancies, are being conducted around the world each year.
New studies and clinical trials are posted here as, they become available.
New studies and clinical trials are posted here as, they become available.
NIH Tells You How to Find a Clinical Trial
How to Find a Clinical Trial
AACR Research Opportunities
Appendix Cancer Clinical Trials
Pseudomyxoma Peritonei Clinical Trials
Listing of open and closed Pseudomyxoma Peritonei clinical trials in the US.
Source: ClinicalTrials.gov
Source: ClinicalTrials.gov
Appendiceal Cancer and Peritoneal Carcinomatosis Clinical Trials
Listing of open and closed Appendix Cancer and Peritoneal Carcinomatosis clinical trials in the US.
Source:ClinicalTrials.gov
Source:ClinicalTrials.gov
Appendix, Colorectal Cancer and Peritoneal Carcinomatosis Clinical Trials
Global Listing of Appendix Cancer Research Specialists
Dr Steven Ahrendt, Surgical Oncologist, UPMC, Pgh PA
Peritoneal Cancer Research by Dr Steven A Ahrendt and colleagues
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Dr David L Bartlett, Surgeon, UPMC Hillman Cancer Center, Pgh, PA, USA
Read the profile for Dr David L Bartlett and contact him for a consultation
David L Bartlett MD
Hilllman Cancer Center (UPMC), Pgh PA
David C. Koch Regional Perfusion
5150 Center Avenue Pittsburgh, PA 15232
Phone: (412) 692-2852
Assistant to Dr David L Bartlett: Heather Jones, PA
Office Manager: Margaret J Corson
UPMC Koch Center Program Manager: Maureen Hewko, via email at hewkom@upmc.edu
PSEUDOMYXOMA PERITONEI PMP CURE, PERITONEAL CARCINOMATOSIS, APPENDIX CANCER, COLON CANCER, OVARIAN CANCER, PANCREATIC CANCER
Specializing in developing clinical trials and investigative research to discover cancer's underlying immunobiology, and to design and implement the most effective treatment(s.)
Development of tumor selective viral vectors/development of surgical procedures for regional treatment of malignant neoplasms.
Donations for Dr Bartlett's research can be sent:
via postal mail University of Pittsburgh Cancer Institute Development,
UPMC Cancer Pavilion – Suite 1B
5150 Centre Avenue, Pgh, PA 15232
or via telephone/credit card, contact Eleanor Flannery (412 )623-4700
or to inquire about making donations, contact Eleanor Flannery via flanneryel@upmc.edu
or via online directly at UPMC Cancer Centers by selecting "UPCI" under the "Online Securely Donate" section
The Koch Regional Cancer Therapy Center is committed to:
* Promoting Research, Development and Application of Regional Cancer Therapies
* Exchanging Information and Promoting Education Among Professionals regarding Regional Cancer Therapies
Pseudomyxoma Peritonei and Peritoneal Carcinomatosis research articles by Dr David L Bartlett
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Anuals of Surgical Oncology, 2008
HIPEC: The Complexity of Clinical Trials
Source: Dr David L Bartlett, UPMC, Society of Surgical Oncology 2008
Liver Cancer Research by Dr David L Bartlett
Dr David L Bartlett: Treatment of Liver Cancer
Source: UPMC Koch Cancer Center
David L Bartlett MD
Hilllman Cancer Center (UPMC), Pgh PA
David C. Koch Regional Perfusion
5150 Center Avenue Pittsburgh, PA 15232
Phone: (412) 692-2852
Assistant to Dr David L Bartlett: Heather Jones, PA
Office Manager: Margaret J Corson
UPMC Koch Center Program Manager: Maureen Hewko, via email at hewkom@upmc.edu
PSEUDOMYXOMA PERITONEI PMP CURE, PERITONEAL CARCINOMATOSIS, APPENDIX CANCER, COLON CANCER, OVARIAN CANCER, PANCREATIC CANCER
Specializing in developing clinical trials and investigative research to discover cancer's underlying immunobiology, and to design and implement the most effective treatment(s.)
Development of tumor selective viral vectors/development of surgical procedures for regional treatment of malignant neoplasms.
Donations for Dr Bartlett's research can be sent:
via postal mail University of Pittsburgh Cancer Institute Development,
UPMC Cancer Pavilion – Suite 1B
5150 Centre Avenue, Pgh, PA 15232
or via telephone/credit card, contact Eleanor Flannery (412 )623-4700
or to inquire about making donations, contact Eleanor Flannery via flanneryel@upmc.edu
or via online directly at UPMC Cancer Centers by selecting "UPCI" under the "Online Securely Donate" section
The Koch Regional Cancer Therapy Center is committed to:
* Promoting Research, Development and Application of Regional Cancer Therapies
* Exchanging Information and Promoting Education Among Professionals regarding Regional Cancer Therapies
Pseudomyxoma Peritonei and Peritoneal Carcinomatosis research articles by Dr David L Bartlett
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Anuals of Surgical Oncology, 2008
HIPEC: The Complexity of Clinical Trials
Source: Dr David L Bartlett, UPMC, Society of Surgical Oncology 2008
Liver Cancer Research by Dr David L Bartlett
Dr David L Bartlett: Treatment of Liver Cancer
Source: UPMC Koch Cancer Center
HIPEC: Cinical Trials
ASPSM
Dr David L Bartlett is a member of the ASPSM
Dr Wim P Ceelen, Surgeon, Ghent University, Belgium
Prof dr Wim P Ceelen, MD, PhD, FACS Dienst Gastro-intestinale Heelkunde
Universitair Ziekenhuis Gent Department of Gastrointestinal Surgery
Ghent University Hospital De Pintelaan 185, B-9000 Gent, Belgium
Tel +32 9 332 62 51 Fax +32 9 332 38 91
wim.ceelen@ugent.be
HIPEC TREATMENT RESEARCH
Dr Wim P Ceelen, MD, PhD, FACS is studying an animal model for HIPEC treatment.
Dr Wim P Ceelen be reached via:
Department of Surgery
University Hospital, De Pintelaan 185
B-9000 Gent, Belgium
Tel +32 9 332 62 51
Fax +32 9 332 38 91
Email to wim.ceelen@ugent.be
Website:http://www.surgery.ugent.be
Source: Dr Wim P Ceelen provided this information to the PMP Pals' Network
Universitair Ziekenhuis Gent Department of Gastrointestinal Surgery
Ghent University Hospital De Pintelaan 185, B-9000 Gent, Belgium
Tel +32 9 332 62 51 Fax +32 9 332 38 91
wim.ceelen@ugent.be
HIPEC TREATMENT RESEARCH
Dr Wim P Ceelen, MD, PhD, FACS is studying an animal model for HIPEC treatment.
Dr Wim P Ceelen be reached via:
Department of Surgery
University Hospital, De Pintelaan 185
B-9000 Gent, Belgium
Tel +32 9 332 62 51
Fax +32 9 332 38 91
Email to wim.ceelen@ugent.be
Website:http://www.surgery.ugent.be
Source: Dr Wim P Ceelen provided this information to the PMP Pals' Network
ASPSM
Dr Marcello Deraco is a member of the ASPSM
Dr Jesus Esquivel, Surgeon, St Agnes Hospital, USA
Jesus Esquivel, MD, FACS, Director
Peritoneal Surface Malignancy Program
St. Agnes Hospital 900 Caton Ave Mail Box 207
Baltimore, Maryland 21229
Phone: 410-368-2743 Fax: 410-951-4007
email: jesquive@stagnes.org web: www.hipec.org
Assistant to Dr Esquivel, Robin Cianos RN
PERITONEAL SURFACE MALIGNANCIES, HIPEC, PSEUDOMYXOMA PERITONEI CURE RESEARCH
Laparoscopic CRS and HIPEC for Patients with limited Peritoneal Surface Malignancies
RPN: 2008-20
Protocol Status: Closed. Results of study are posted here:
Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Limited Peritoneal Surface Malignancies: Feasibility, Morbidity and Outcome in an Early Experience.
Dr Jesus Esquivel, and his colleagues at St. Agnes Hospital in Baltimore, MD, is reporting on their initial evaluation of the feasibility and safety of laparoscopic (minimally invasive) cytoreductive surgery (CRS) and HIPEC. An abstract of their study is posted on the HIPEC Treatments page at www.pmppals.org
The majority of patients who participated in this study were initially diagnosed with appendiceal malignancies, with low-tumor volume and no small bowel involvement mainly from. Ann Surg. 2011 Jan 6.
Abstract
INTRODUCTION: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are being widely used in the treatment of patients with peritoneal surface malignancies. The open procedure has been associated with high grade III and IV morbidity and prolonged hospitalization.
METHODS: Patients with peritoneal surface malignancies and no gross evidence of carcinomatosis on the computed tomographic scan were enrolled to undergo laparoscopic CRS and HIPEC. We aimed to assess the feasibility, safety, and outcome of this procedure. Postoperative complications were reported according to the National Cancer Institute Common Toxicity Criteria.
RESULTS: From October 2008 to January 2010, 14 patients were enrolled into the protocol. Amongst these 14 patients, one patient was found with extensive carcinomatosis at the time of laparoscopy and had no surgical procedure. Thirteen patients had a complete cytoreduction and HIPEC, 10 (77%) laparoscopically and 3 (23%) were converted to an open procedure. There was one grade 3 morbidity (10%) and one patient (10%) in the laparoscopy group experienced a grade 4 complication, needing a reoperation for an internal hernia. Mean length of hospital stay was 6 days for those completed laparoscopically, 8 days for those converted to an open procedure and 8 days for a matched cohort of patients with an upfront open procedure.
CONCLUSIONS: This initial investigative stage demonstrates the feasibility and safety of cytoreductive surgery and HIPEC via the laparoscopic route in selected patients with low-tumor volume and no small bowel involvement mainly from appendiceal malignancies. Longer follow-up and additional studies are required to evaluate its long-term efficacy.
Donations to Dr Esquivel's research may be sent to:
Jesus Esquivel, MD, FACS
Director, Peritoneal Surface Malignancy Program
St. Agnes Hospital
900 Caton Ave
Mail Box 207
Baltimore, Maryland 21229 USA
Phone: 410-368-2743
Fax: 410-951-4007
email: jesquive@stagnes.org
web: www.hipec.org
Source: Dr Jesus Esquivel provided this information to the PMP Pals' Network
Appendix Cancer Research and HIPEC Research Articles by Dr Jesus Esquivel
Peritoneal Surface Malignancy Program
St. Agnes Hospital 900 Caton Ave Mail Box 207
Baltimore, Maryland 21229
Phone: 410-368-2743 Fax: 410-951-4007
email: jesquive@stagnes.org web: www.hipec.org
Assistant to Dr Esquivel, Robin Cianos RN
PERITONEAL SURFACE MALIGNANCIES, HIPEC, PSEUDOMYXOMA PERITONEI CURE RESEARCH
Laparoscopic CRS and HIPEC for Patients with limited Peritoneal Surface Malignancies
RPN: 2008-20
Protocol Status: Closed. Results of study are posted here:
Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Limited Peritoneal Surface Malignancies: Feasibility, Morbidity and Outcome in an Early Experience.
Dr Jesus Esquivel, and his colleagues at St. Agnes Hospital in Baltimore, MD, is reporting on their initial evaluation of the feasibility and safety of laparoscopic (minimally invasive) cytoreductive surgery (CRS) and HIPEC. An abstract of their study is posted on the HIPEC Treatments page at www.pmppals.org
The majority of patients who participated in this study were initially diagnosed with appendiceal malignancies, with low-tumor volume and no small bowel involvement mainly from. Ann Surg. 2011 Jan 6.
Abstract
INTRODUCTION: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are being widely used in the treatment of patients with peritoneal surface malignancies. The open procedure has been associated with high grade III and IV morbidity and prolonged hospitalization.
METHODS: Patients with peritoneal surface malignancies and no gross evidence of carcinomatosis on the computed tomographic scan were enrolled to undergo laparoscopic CRS and HIPEC. We aimed to assess the feasibility, safety, and outcome of this procedure. Postoperative complications were reported according to the National Cancer Institute Common Toxicity Criteria.
RESULTS: From October 2008 to January 2010, 14 patients were enrolled into the protocol. Amongst these 14 patients, one patient was found with extensive carcinomatosis at the time of laparoscopy and had no surgical procedure. Thirteen patients had a complete cytoreduction and HIPEC, 10 (77%) laparoscopically and 3 (23%) were converted to an open procedure. There was one grade 3 morbidity (10%) and one patient (10%) in the laparoscopy group experienced a grade 4 complication, needing a reoperation for an internal hernia. Mean length of hospital stay was 6 days for those completed laparoscopically, 8 days for those converted to an open procedure and 8 days for a matched cohort of patients with an upfront open procedure.
CONCLUSIONS: This initial investigative stage demonstrates the feasibility and safety of cytoreductive surgery and HIPEC via the laparoscopic route in selected patients with low-tumor volume and no small bowel involvement mainly from appendiceal malignancies. Longer follow-up and additional studies are required to evaluate its long-term efficacy.
Donations to Dr Esquivel's research may be sent to:
Jesus Esquivel, MD, FACS
Director, Peritoneal Surface Malignancy Program
St. Agnes Hospital
900 Caton Ave
Mail Box 207
Baltimore, Maryland 21229 USA
Phone: 410-368-2743
Fax: 410-951-4007
email: jesquive@stagnes.org
web: www.hipec.org
Source: Dr Jesus Esquivel provided this information to the PMP Pals' Network
Appendix Cancer Research and HIPEC Research Articles by Dr Jesus Esquivel
Learning Curve for CRS and HIPEC
Source: Journal of Surgical Oncology, August 2009
Laparoscopic CRS and HIPEC Treatment for Peritoneal Mesothelioma
Source: Dr Jesus Esquivel, 2009
HIPEC Treatment available at St Agnes Hospital
Source: Dr Jesus Esquivel
Pros and Cons of HIPEC: Dr Jesus Esquivel
Source: Oncology Times, Jan 2007
Source: Journal of Surgical Oncology, August 2009
Laparoscopic CRS and HIPEC Treatment for Peritoneal Mesothelioma
Source: Dr Jesus Esquivel, 2009
HIPEC Treatment available at St Agnes Hospital
Source: Dr Jesus Esquivel
Pros and Cons of HIPEC: Dr Jesus Esquivel
Source: Oncology Times, Jan 2007
ASPSM
Dr Jesus Esquivel is a member of the ASPSM
Dr Jan Franko, Surgical Oncologist, Mercy Medical Center, USA
Click here to read Dr Jan Franko's professional profile
Jan Franko, MD, PhD, FACS
Surgical Oncology & Endocrine Surgery
Mercy Medical Center
411 Laurel St, Ste 2100
Des Moines, IA 50314
Appendix Cancer Research by Dr Jan Franko
Case-matched comparison of survival after cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion for peritoneal carcinomatosis versus liver resection for metastatic colorectal cancer.
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis vs Liver Resection for Colorectal Cancer
Authors:J. Franko, N. J. Gusani, M. P. Holtzman, S. A. Ahrendt, H. J. Zeh, D. L. Bartlett
Source of Abstract: ASCO 2011
Background: Cytoreductive surgery combined with peritoneal hyperthermic chemoperfusion (CS-HIPEC) is an emerging option for patients with peritoneal carcinomatosis from metastatic colorectal cancer (mCRC). Conduction of further surgical randomized trails has proven unfeasible. On the other hand, the survival benefit derived from liver resection for mCRC is well recognized. Both resection of liver metastases and CS-HIPEC are considered regional therapies. Therefore we compared the outcome of CS-HIPEC to the known benefit in patients resected for liver metastases from mCRC.
Methods: All consecutive patients with peritoneal carcinomatosis from mCRC treated by CS-HIPEC at our institution in 2001-2006 were included. Hyperthemic perfusion of peritoneal cavity with 40 mg of mitomycin C for 100 minutes was performed after surgical cytoreduction. The control group was frequency matched 1:4 for age, gender and tumor grade (n=248) and consisted of patients undergoing colorectal and liver resection for mCRC. These cases were extracted from the Surveillance, Epidemiology, and End Results Program. Overall survival was the primary end-point.
Results: 62 procedures were performed in 57 patients. Initial systemic chemotherapy was performed in all but one patient in the CS-HIPEC group. Median survival was 28.0 months in the control group versus 25.8 months in CS-HIPEC group (p=0.624). One, 2, and 3-year survival was 78, 53, and 36% in the controls versus 84, 55, and 39% in the CS-HIPEC group. A sensitivity analysis including CS-HIPEC cases initially presenting with synchronous peritoneal carcinomatosis (n=22) showed that survival estimator curves remained identical (p=0.793).
Conclusions: Survival benefit in patients undergoing CS-HIPEC is comparable to that derived from liver resection for mCRC. This evidence further supports the role of cytoreductive surgery and hyperthermic chemoperfusion in the treatment of patients with peritoneal carcinomatosis of colorectal origin.
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Selected Bibliography of Jan Franko, MD, PhD, FACS
•Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. (in press) Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ: Cancer 2010. In press.
•Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients. Franko J, Feng W, Yip L, Genovese E, Moser AJ.J Gastrointest Surg. 2009 Dec 9.
•Serous cystadenocarcinoma of the pancreas with metachronous hepatic metastasis. Franko J, Cole K, Pezzi CM, Montone KT, Redmond J. Am J Clin Oncol. 2008 Dec;31(6):624-5
•Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Franko J, Gusani NJ, Holtzman MP, Ahrendt SA, Jones HL, Zeh HJ 3rd, Bartlett DL. Ann Surg Oncol. 2008 Nov;15(11):3065-72. Epub 2008 Aug 19
•Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, Hughes SJ, Bartlett DL, Zeh HJ 3rd, Moser AJ. J Gastrointest Surg. 2008 Oct;12(10):1664-72; discussion 1672-3. Epub 2008 Aug 2
•Conversion of laparoscopic colon resection does not affect survival in colon cancer. Franko J, Fassler SA, Rezvani M, O'Connell BG, Harper SG, Nejman JH, Zebley DM. Surg Endosc. 2008 Dec;22(12):2631-4. Epub 2008 Feb 23
•Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL. Ann Surg Oncol. 2008 Mar;15(3):754-63
•Outcomes in patients treated by laparoscopic resection of rectal carcinoma after neoadjuvant therapy for rectal cancer. Rezvani M, Franko J, Fassler SA, Harper SG, Nejman JH, Zebley DM. JSLS. 2007 Apr-Jun;11(2):204-7
•Multimodality therapy for pancreatic cancer. Franko J, Greer JB, Moran CM, Khalid A, Moser AJ. Gastroenterol Clin North Am. 2007 Jun;36(2):391-411
•Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Ann Surg Oncol. 2007 Jan;14(1):166-73. Epub 2006 Oct 26
•The influence of prior abdominal operations on conversion and complication rates in laparoscopic colorectal surgery. Franko J, O'Connell BG, Mehall JR, Harper SG, Nejman JH, Zebley DM, Fassler SA. JSLS. 2006 Apr-Jun;10(2):169-75
•Choledochal cyst cholangiocarcinoma arising from adenoma: case report and a review of the literature. Franko J, Nussbaum ML, Morris JB. Curr Surg. 2006 Jul-Aug;63(4):281-4
•Safely increasing the efficiency of thyroidectomy using a new bipolar electrosealing device (LigaSure) versus conventional clamp-and-tie technique. Franko J, Kish KJ, Pezzi CM, Pak H, Kukora JS. Am Surg. 2006 Feb;72(2):132-6
•Intraabdominal pulmonary sequestration. Franko J, Bell K, Pezzi CM. Curr Surg. 2006 Jan-Feb;63(1):35-8
Jan Franko, MD, PhD, FACS
Surgical Oncology & Endocrine Surgery
Mercy Medical Center
411 Laurel St, Ste 2100
Des Moines, IA 50314
Appendix Cancer Research by Dr Jan Franko
Case-matched comparison of survival after cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion for peritoneal carcinomatosis versus liver resection for metastatic colorectal cancer.
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis vs Liver Resection for Colorectal Cancer
Authors:J. Franko, N. J. Gusani, M. P. Holtzman, S. A. Ahrendt, H. J. Zeh, D. L. Bartlett
Source of Abstract: ASCO 2011
Background: Cytoreductive surgery combined with peritoneal hyperthermic chemoperfusion (CS-HIPEC) is an emerging option for patients with peritoneal carcinomatosis from metastatic colorectal cancer (mCRC). Conduction of further surgical randomized trails has proven unfeasible. On the other hand, the survival benefit derived from liver resection for mCRC is well recognized. Both resection of liver metastases and CS-HIPEC are considered regional therapies. Therefore we compared the outcome of CS-HIPEC to the known benefit in patients resected for liver metastases from mCRC.
Methods: All consecutive patients with peritoneal carcinomatosis from mCRC treated by CS-HIPEC at our institution in 2001-2006 were included. Hyperthemic perfusion of peritoneal cavity with 40 mg of mitomycin C for 100 minutes was performed after surgical cytoreduction. The control group was frequency matched 1:4 for age, gender and tumor grade (n=248) and consisted of patients undergoing colorectal and liver resection for mCRC. These cases were extracted from the Surveillance, Epidemiology, and End Results Program. Overall survival was the primary end-point.
Results: 62 procedures were performed in 57 patients. Initial systemic chemotherapy was performed in all but one patient in the CS-HIPEC group. Median survival was 28.0 months in the control group versus 25.8 months in CS-HIPEC group (p=0.624). One, 2, and 3-year survival was 78, 53, and 36% in the controls versus 84, 55, and 39% in the CS-HIPEC group. A sensitivity analysis including CS-HIPEC cases initially presenting with synchronous peritoneal carcinomatosis (n=22) showed that survival estimator curves remained identical (p=0.793).
Conclusions: Survival benefit in patients undergoing CS-HIPEC is comparable to that derived from liver resection for mCRC. This evidence further supports the role of cytoreductive surgery and hyperthermic chemoperfusion in the treatment of patients with peritoneal carcinomatosis of colorectal origin.
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Selected Bibliography of Jan Franko, MD, PhD, FACS
•Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. (in press) Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ: Cancer 2010. In press.
•Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients. Franko J, Feng W, Yip L, Genovese E, Moser AJ.J Gastrointest Surg. 2009 Dec 9.
•Serous cystadenocarcinoma of the pancreas with metachronous hepatic metastasis. Franko J, Cole K, Pezzi CM, Montone KT, Redmond J. Am J Clin Oncol. 2008 Dec;31(6):624-5
•Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Franko J, Gusani NJ, Holtzman MP, Ahrendt SA, Jones HL, Zeh HJ 3rd, Bartlett DL. Ann Surg Oncol. 2008 Nov;15(11):3065-72. Epub 2008 Aug 19
•Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, Hughes SJ, Bartlett DL, Zeh HJ 3rd, Moser AJ. J Gastrointest Surg. 2008 Oct;12(10):1664-72; discussion 1672-3. Epub 2008 Aug 2
•Conversion of laparoscopic colon resection does not affect survival in colon cancer. Franko J, Fassler SA, Rezvani M, O'Connell BG, Harper SG, Nejman JH, Zebley DM. Surg Endosc. 2008 Dec;22(12):2631-4. Epub 2008 Feb 23
•Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL. Ann Surg Oncol. 2008 Mar;15(3):754-63
•Outcomes in patients treated by laparoscopic resection of rectal carcinoma after neoadjuvant therapy for rectal cancer. Rezvani M, Franko J, Fassler SA, Harper SG, Nejman JH, Zebley DM. JSLS. 2007 Apr-Jun;11(2):204-7
•Multimodality therapy for pancreatic cancer. Franko J, Greer JB, Moran CM, Khalid A, Moser AJ. Gastroenterol Clin North Am. 2007 Jun;36(2):391-411
•Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Ann Surg Oncol. 2007 Jan;14(1):166-73. Epub 2006 Oct 26
•The influence of prior abdominal operations on conversion and complication rates in laparoscopic colorectal surgery. Franko J, O'Connell BG, Mehall JR, Harper SG, Nejman JH, Zebley DM, Fassler SA. JSLS. 2006 Apr-Jun;10(2):169-75
•Choledochal cyst cholangiocarcinoma arising from adenoma: case report and a review of the literature. Franko J, Nussbaum ML, Morris JB. Curr Surg. 2006 Jul-Aug;63(4):281-4
•Safely increasing the efficiency of thyroidectomy using a new bipolar electrosealing device (LigaSure) versus conventional clamp-and-tie technique. Franko J, Kish KJ, Pezzi CM, Pak H, Kukora JS. Am Surg. 2006 Feb;72(2):132-6
•Intraabdominal pulmonary sequestration. Franko J, Bell K, Pezzi CM. Curr Surg. 2006 Jan-Feb;63(1):35-8
Dr Charles Goldman, Surgeon, Mercy Medical Center, USA
Dr Martin Goodman, Surgeon, Tufts University, USA
Read the profile for Dr Martin Goodman and contact him directly for a consultation
Martin Goodman MD FACS Assistant Professor of Surgery
Director of the Peritoneal Surface Malignancy Program
Tufts Medical Center 800 Washington St #9248 Boston MA 02111
P:617-636-9248
Email mgoodman@tuftsmedicalcenter.org
Website www.tuftsmedicalcenter.org
Martin Goodman MD FACS Assistant Professor of Surgery
Director of the Peritoneal Surface Malignancy Program
Tufts Medical Center 800 Washington St #9248 Boston MA 02111
P:617-636-9248
Email mgoodman@tuftsmedicalcenter.org
Website www.tuftsmedicalcenter.org
Photo of Dr Martin Goodman at the PMP Pals' Network Conference
Copyright © PMP Pals’ Network
PERITONEAL SURFACE MALIGNANCIES, PSEUDOMYXOMA PERITONEI RESEARCH, HIPEC RESEARCH
Research interests:
Clinical
Investigation to decrease complication rates from an anesthetic prospective during HIPEC
Building a data base to evaluate outcomes and trends as well as help decrease the complication rates of HIPEC
Safety analysis to the OR staff from the chemotherapeutic drugs
Participating in multi institutional study evaluating HIPEC for colon cancer
Translational and Basic Science
Working with pathology to look for unique stains and markers for outcomes
Working with a biotechnologist to look for specific DNA and RNA in mucinous tumors and methods to stop mucin production
Source: Dr Martin Goodman provided this information to the PMP Pals' Network
Help Dr Goodman to develop a cure for Appendix Cancer and PMP by donating to his research online via at:
www.tuftsmedicalcenter.org/giving/make a gift under "Surgery and Peritoneal Surface Malignancy Fund."
Make check payable to the:
Peritoneal Surface Malignancy Fund
800 Washington St Box #9248
Boston MA 02111
ASPSM
Dr Martin Goodman is a member of the ASPSM
Prof. Dr Joachim Jaehne, Klinik fur Allgemein, Germany
Prof. Dr. Joachim Jaehne,
DKH Oncologic Surgery, Hannover, Germany
Klinik für Allgemein- und Viszeralchirurgie
Schwerpunkt für endokrine und onkologische Chirurgie
Diakoniekrankenhaus Henriettenstiftung gGmbH
Marienstr. 72-90 D-30171 Hannover
Tel.: +495112892101 Fax: +495112892022
e-mail: joachim.jaehne@ddh-gruppe.de
www.diakoniekrankenhaus-henriettenstiftung.de
DKH Oncologic Surgery, Hannover, Germany
Klinik für Allgemein- und Viszeralchirurgie
Schwerpunkt für endokrine und onkologische Chirurgie
Diakoniekrankenhaus Henriettenstiftung gGmbH
Marienstr. 72-90 D-30171 Hannover
Tel.: +495112892101 Fax: +495112892022
e-mail: joachim.jaehne@ddh-gruppe.de
www.diakoniekrankenhaus-henriettenstiftung.de
ASPSM
Dr Matthew P Holtzman is a member of the ASPSM
Dr Laura Lambert, Surgeon, UMass, USA
Read the profile for Dr Laura Lambert and contact her directly
Laura A. Lambert, MD
Adult Specialties Surgery - Oncology
UMass Memorial Medical Center - Memorial Campus
119 Belmont Street
Worcester, MA 01605
Tel: 508-334-5274 Fax: 508-334-5089
PERITONEAL SURFACE MALIGNANCY, PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH, APPENDICEAL CANCER, HIPEC
Dr Laura L Lambert is conducting the following research via the UMass Memorial Medical Center
Peritoneal Surface Malignancy Research Program:
1. Alternative solutions in hyperthermic intraperitoneal perfusion
Cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IC) are considered the standard of care for patients with peritoneal dissemination of appendiceal cancer, ovarian cancer and peritoneal mesothelioma. Data are also accumulating that show a survival advantage for this approach in selected patients with carcinomatosis for colorectal cancer. However, there is no consensus as to the optimal form of IC. Usage of a wide variety of chemotherapy agents, in various carrier solutions, administered either with or without hyperthermia, for a broad range of times (30 minutes to days), has been reported with remarkably comparable rates of success. Consequently, the optimal form of IC is unknown, while on the other hand, clinically significant systemic side effects are well-documented. The main goal of this project is to investigate alternative peritoneal perfusion techniques that result in tumor –specific cell death with less systemic toxicity. Identification of tumor-specific cytotoxic peritoneal perfusates will improve oncologic outcomes combined with decreased toxicity for patients undergoing CRS and HIPEC.
2. DNA and Protein microarray investigation of appendiceal cancer
Because non-carcinoid appendical cancers are extremely rare, little is known about the genetic pathways that are involved in the growth and dissemination of these tumors. The purpose of this research project is to investigate the genetic and protein expression profiles of non-carcinoid appendiceal cancers. The potential benefits of this project are to identify novel targets for therapy, provide better prognostic information, and identify people at risk for developing appendiceal cancer based upon genetic and protein profiles.
3. Cell cycle-targeted therapy enhances tumor cell death during HIPEC
The ultimate goal of all cancer therapy is cancer-specific cell death, without harming normal cells. Because all cancer cells lose regulation of their cell cycle, cancer therapies that target the cell cycle are appealing and rational. Recent studies from our laboratory targeted the cell cycle in normal, sarcoma and colon cancer cell lines with a cell cycle inhibitor after exposure to chemotherapy. In these studies, the combined treatment resulted in significantly enhanced cell death in the cancer cell lines, but not in the normal cells. Based upon these findings, the main hypothesis of this project is that increased cytotoxicity by cell cycle inhibition after chemotherapy specifically enhances cancer cell death while sparing normal cells. Our objective is to translate our preliminary findings of cell cycle-induced cancer cell death in to improved outcomes for patients undergoing HIPEC.
4. Cytokine and protein profiles of malignant ascites
Patients with peritoneal ascites often suffer debilitating symptoms including life-threatening anorexia and cachexia. Symptom management is challenging and often inadequate, resulting in loss of quality of life (QoL). This study is investigating the cytokine and other protein profiles of malignant and non-malignant ascites for potential targets for palliation. This is an on-going prospective, observational study at the UMass Memorial Medical Center. Patients with ascites retrieved either at surgery or by paracentesis are asked to complete a brief QoL questionnaire. Relative intensity of cytokine and protein expression in the ascites fluid is quantified. Significant differences between non-malignant and malignant ascites are determined and correlated with QoL data. Through this study we hope to identify targets for more effective palliation of symptomatic ascites. So far we have identified angiogenin as a potential target for anti-angiogenic therapy in malignant ascites. In addition, the appetite suppressant, leptin, may be a potential target for palliation of ascites-related anorexia.
5. The role of mucin-regulating hormones in pseudomyxoma peritonei (PMP)
Luteinizing hormone (LH) and beta human chorionogranin (b-HCG) have been shown to play a significant role in the production of gynecologic-associated mucins. The role of sex hormones in the production of gastrointestinal mucin, including that produced by the appendix, has never been determined. The purpose of this project is to investigate the role of sex hormones in the production of gastrointestinal mucin. The potential benefit of the results of this study is to identify a hormone-based therapy for the management of PMP.
Help Dr Lambert develop a cure for Appendiceal Cancer and PMP by sending donations to:
Please make your check payable to UMMF.
IMPORTANT: You MUST write “Laura Lambert MD Research Fund” in the “memo/for” field on your check to direct your gift to the correct fund.
UMass Medical School/UMass Memorial Development Office
UMass Memorial Peritoneal Surface Malignancy Research Program Fund
333 South StreetShrewsbury, MA 01545
For questions regarding your gift please visit Ways of Giving or call 508-856-5520.
This research program is classified as a 501(c)(3).
Source: Dr Lambert provided this information to the PMP Pals' Network
Research by Dr Laura Lambert and Dr Paul Mansfield
CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Laura A. Lambert, MD
Adult Specialties Surgery - Oncology
UMass Memorial Medical Center - Memorial Campus
119 Belmont Street
Worcester, MA 01605
Tel: 508-334-5274 Fax: 508-334-5089
PERITONEAL SURFACE MALIGNANCY, PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH, APPENDICEAL CANCER, HIPEC
Dr Laura L Lambert is conducting the following research via the UMass Memorial Medical Center
Peritoneal Surface Malignancy Research Program:
1. Alternative solutions in hyperthermic intraperitoneal perfusion
Cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IC) are considered the standard of care for patients with peritoneal dissemination of appendiceal cancer, ovarian cancer and peritoneal mesothelioma. Data are also accumulating that show a survival advantage for this approach in selected patients with carcinomatosis for colorectal cancer. However, there is no consensus as to the optimal form of IC. Usage of a wide variety of chemotherapy agents, in various carrier solutions, administered either with or without hyperthermia, for a broad range of times (30 minutes to days), has been reported with remarkably comparable rates of success. Consequently, the optimal form of IC is unknown, while on the other hand, clinically significant systemic side effects are well-documented. The main goal of this project is to investigate alternative peritoneal perfusion techniques that result in tumor –specific cell death with less systemic toxicity. Identification of tumor-specific cytotoxic peritoneal perfusates will improve oncologic outcomes combined with decreased toxicity for patients undergoing CRS and HIPEC.
2. DNA and Protein microarray investigation of appendiceal cancer
Because non-carcinoid appendical cancers are extremely rare, little is known about the genetic pathways that are involved in the growth and dissemination of these tumors. The purpose of this research project is to investigate the genetic and protein expression profiles of non-carcinoid appendiceal cancers. The potential benefits of this project are to identify novel targets for therapy, provide better prognostic information, and identify people at risk for developing appendiceal cancer based upon genetic and protein profiles.
3. Cell cycle-targeted therapy enhances tumor cell death during HIPEC
The ultimate goal of all cancer therapy is cancer-specific cell death, without harming normal cells. Because all cancer cells lose regulation of their cell cycle, cancer therapies that target the cell cycle are appealing and rational. Recent studies from our laboratory targeted the cell cycle in normal, sarcoma and colon cancer cell lines with a cell cycle inhibitor after exposure to chemotherapy. In these studies, the combined treatment resulted in significantly enhanced cell death in the cancer cell lines, but not in the normal cells. Based upon these findings, the main hypothesis of this project is that increased cytotoxicity by cell cycle inhibition after chemotherapy specifically enhances cancer cell death while sparing normal cells. Our objective is to translate our preliminary findings of cell cycle-induced cancer cell death in to improved outcomes for patients undergoing HIPEC.
4. Cytokine and protein profiles of malignant ascites
Patients with peritoneal ascites often suffer debilitating symptoms including life-threatening anorexia and cachexia. Symptom management is challenging and often inadequate, resulting in loss of quality of life (QoL). This study is investigating the cytokine and other protein profiles of malignant and non-malignant ascites for potential targets for palliation. This is an on-going prospective, observational study at the UMass Memorial Medical Center. Patients with ascites retrieved either at surgery or by paracentesis are asked to complete a brief QoL questionnaire. Relative intensity of cytokine and protein expression in the ascites fluid is quantified. Significant differences between non-malignant and malignant ascites are determined and correlated with QoL data. Through this study we hope to identify targets for more effective palliation of symptomatic ascites. So far we have identified angiogenin as a potential target for anti-angiogenic therapy in malignant ascites. In addition, the appetite suppressant, leptin, may be a potential target for palliation of ascites-related anorexia.
5. The role of mucin-regulating hormones in pseudomyxoma peritonei (PMP)
Luteinizing hormone (LH) and beta human chorionogranin (b-HCG) have been shown to play a significant role in the production of gynecologic-associated mucins. The role of sex hormones in the production of gastrointestinal mucin, including that produced by the appendix, has never been determined. The purpose of this project is to investigate the role of sex hormones in the production of gastrointestinal mucin. The potential benefit of the results of this study is to identify a hormone-based therapy for the management of PMP.
Help Dr Lambert develop a cure for Appendiceal Cancer and PMP by sending donations to:
Please make your check payable to UMMF.
IMPORTANT: You MUST write “Laura Lambert MD Research Fund” in the “memo/for” field on your check to direct your gift to the correct fund.
UMass Medical School/UMass Memorial Development Office
UMass Memorial Peritoneal Surface Malignancy Research Program Fund
333 South StreetShrewsbury, MA 01545
For questions regarding your gift please visit Ways of Giving or call 508-856-5520.
This research program is classified as a 501(c)(3).
Source: Dr Lambert provided this information to the PMP Pals' Network
Research by Dr Laura Lambert and Dr Paul Mansfield
CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Dr Laura Lambert, UMass
ASPSM
Dr Laura Lambert is a member of the ASPSM
Dr Edward A Levine, Surgeon, Wake Forest University, USA
Read the profile for Dr Edward A Levine and contact him directly
APPENDIX CANCER CLINICAL TRIALS, COLORECTAL, HIPEC, PSEUDOMYXOMA PERITONEI RESEARCH,PERITONEAL SURFACE DISEASES
Edward A. Levine, M.D., Professor of Surgery and Chief of Surgical Oncology at Wake Forest University in Winston-Salem, North Carolina , USA, and his colleagues, conduct three trials related to the care of patients diagnosed with Appendix cancers and Peritoneal surface diseases. Additionally, this research team participates in a national registry for HIPEC cases. These studies include the following:
1. research into quality of life following the HIPEC procedures.
2. a tumor bank program saving tumor tissue for a variety of research efforts into the molecular events related to peritoneal surface disease.
3. a phase I-II trial evaluating Oxaliplatin in perfusion for patients undergoing HIPEC for Colorectal or Appendix cancer primary carcinomatosis.
Wake Forest University studies mice in the research of Granulocytes to reduce/eliminate tumors
For more information, in general call 336 716 4276, EST.
To schedule appointments or to ask for specific questions regarding research, call Joyce Fenstermaker R.N. at 336 713 3155, EST
PMP Research by Dr Edward Levine
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008
“Appendiceal Carcinoma with Peritoneal Dissemination: Outcomes for the Best of the Best.”
Source: Annals of Surgical Oncology,2007, Dr Edward Levine, WFU
Survival Study for Pseudomyxoma Peritonei: DPAM, PMCA, PMCA 1
Source: Dr Edward Levine, American Journal of Surgical Pathology, May 2006
DPAM and HIPEC Treatment
Source: Wake Forest University
APPENDIX CANCER CLINICAL TRIALS, COLORECTAL, HIPEC, PSEUDOMYXOMA PERITONEI RESEARCH,PERITONEAL SURFACE DISEASES
Edward A. Levine, M.D., Professor of Surgery and Chief of Surgical Oncology at Wake Forest University in Winston-Salem, North Carolina , USA, and his colleagues, conduct three trials related to the care of patients diagnosed with Appendix cancers and Peritoneal surface diseases. Additionally, this research team participates in a national registry for HIPEC cases. These studies include the following:
1. research into quality of life following the HIPEC procedures.
2. a tumor bank program saving tumor tissue for a variety of research efforts into the molecular events related to peritoneal surface disease.
3. a phase I-II trial evaluating Oxaliplatin in perfusion for patients undergoing HIPEC for Colorectal or Appendix cancer primary carcinomatosis.
Wake Forest University studies mice in the research of Granulocytes to reduce/eliminate tumors
For more information, in general call 336 716 4276, EST.
To schedule appointments or to ask for specific questions regarding research, call Joyce Fenstermaker R.N. at 336 713 3155, EST
PMP Research by Dr Edward Levine
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008
“Appendiceal Carcinoma with Peritoneal Dissemination: Outcomes for the Best of the Best.”
Source: Annals of Surgical Oncology,2007, Dr Edward Levine, WFU
Survival Study for Pseudomyxoma Peritonei: DPAM, PMCA, PMCA 1
Source: Dr Edward Levine, American Journal of Surgical Pathology, May 2006
DPAM and HIPEC Treatment
Source: Wake Forest University
ASPSM
Dr Edward A Levine is a member of the ASPSM
Wake Forest University Comprehensive Cancer Treatment Center
Dr Edward A Levine provides HIPEC treatment at the Wake Forest University Comprehensive Cancer Treatment Center
APPENDIX CANCER CLINICAL TRIALS, COLORECTAL, HIPEC, PERITONEAL SURFACE DISEASES
Three trials related to the care of patients diagnosed with Appendix cancers and Peritoneal surface diseases are being conducted at Wake Forest University. These studies include the following:
1. research into quality of life following the HIPEC procedures.
2. a tumor bank program saving tumor tissue for a variety of research efforts into the molecular events related to peritoneal surface disease.
3. a phase I-II trial evaluating Oxaliplatin in perfusion for patients undergoing HIPEC for Colorectal or Appendix cancer primary carcinomatosis.
Wake Forest University studies mice in the research of Granulocytes to reduce/eliminate tumors
For more information, in general call 336 716 4276, EST.
To schedule appointments or to ask for specific questions regarding research, call Joyce Fenstermaker R.N. at 336 713 3155, EST
Dr Steven Libutti, Surgeon, Montefiore-Einstein, USA
Research publications by Dr Steven Libutti and Colleagues
Shen HC, He M, Powell A, Adem A, Lorang D, Heller C, Grover AC, Ylaya K, Hewitt SM, Marx SJ, Spiegel AM, Libutti SK. Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res. 2009 Mar 1;69(5):1858-66. Epub 2009 Feb 10. PMID: 19208834 [PubMed - in process]
Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, Arap W, Adem A,Starker E, Hewitt S, Libutti SK. Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer. 2009 Jan 1;115(1):128-39. PMID: 19090007 [PubMed - in process]
Hanna E, Quick J, Libutti SK. The tumour microenvironment: a novel target for cancer therapy. Oral Dis. 2009 Jan;15(1):8-17. Epub 2008 Nov 1. PMID: 18992016 [PubMed - in process]
Powell AC, Alexander HR, Pingpank JF, Steinberg SM, Skarulis M, Bartlett DL, Agarwal S, Cochran C, Seidel G, Fraker D, Hughes MS, Jensen RT, Marx SJ, Libutti SK. The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery. 2008 Dec;144(6):878-83; discussion 883-4. PMID: 19040992 [PubMed - indexed for MEDLINE]
Kwon M, Hanna E, Lorang D, He M, Quick JS, Adem A,Stevenson C, Chung JY, Hewitt SM, Zudaire E, Esposito D, Cuttitta F, Libutti SK. Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy.Cancer Res. 2008 Sep 15;68(18):7332-41. PMID: 18794120 [PubMed - indexed for MEDLINE]
Powell AC, Stratakis CA, Patronas NJ, Steinberg SM, Batista D, Alexander HR,Pingpank JF, Keil M, Bartlett DL, Libutti SK. Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia. Surgery. 2008 Jun;143(6):750-8. PMID: 18549891 [PubMed - indexed for MEDLINE]
Shen HC, Rosen JE, Yang LM, Savage SA, Burns AL, Mateo CM, Agarwal SK,Chandrasekharappa SC, Spiegel AM, Collins FS, Marx SJ, Libutti SK. Parathyroid tumor development involves deregulation of homeobox genes. Endocr Relat Cancer. 2008 Mar;15(1):267-75. PMID: 18310293 [PubMed - indexed for MEDLINE]
Blansfield JA, Caragacianu D, Alexander HR 3rd, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res. 2008 Jan 1;14(1):270-80. PMID: 18172279 [PubMed - indexed for MEDLINE]
Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR,Seidel G, Shutack Y, Yuldasheva N, Eugeni M, Bartlett DL, Glenn GM, Middelton L, Linehan WM, Libutti SK. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms(PNETs). Surgery. 2007 Dec;142(6):814-8; discussion 818.e1-2. Erratum in: Surgery. 2008 Feb;143(2):302. PMID: 18063061 [PubMed - indexed for MEDLINE]
Dr Brian W Loggie, Surgical Oncologist, Creighton University, Omaha, KS, USA
Read the profile for Dr Brian W Loggie and contact him directly
Brian W. Loggie, MD, CM, FRCSC, FACS
Harold J. Bonnstetter Professor of Surgery
Chief, Division of Surgical Oncology
Creighton University Medical Center
601 N. 30th St, Omaha, NE 68131
Ph: (402) 280-5009 Fax: (402) 280-3448
Assistant to Dr Loggie: Holly Sennett APRN-BC Ph 402-280-4100
PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH, APPENDIX CANCER RESEARCH, DPAM, MESOTHELIOMA
Dr Brian Loggie has created several programs for research in the treatment of PMP and Mesothelioma as follows:
Cox II expression in patients with Pseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
The Cancer Biology program at the Creighton University School of Medicine is directed by Dr. Brian Loggie, professor of surgery, and chief of the division of surgical oncology. He has created a translational working group (TWG) consisting of surgical oncologists, pathologists and basic scientists working collaboratively on several projects relating to Pseudomyxoma Peritonei cure research.
The TWG has begun research identifying mutations in multiple target genes. They are categorizing the mutations on the basis of known signaling pathways in order to combine this knowledge with known pathologic variables and patient outcome. With new biologic insights, it will be possible to consider new approaches to clinical strategies and laboratory testing for PMP patients. The TWG has worked successfully together.
The TWG has previously been successful in identifying novel mutations in the epidermal growth factor (EGFR) gene in Mesothelioma, identifying the biologic implications, confirming the mutation effects on cell signaling function in the laboratory, and devising new treatment strategies.
The TWG seeks to develop information which correlates with prognosis, which aids in developing new treatments, and may guide treatment selection for various presentations and forms of PMP.
The TWG is also continuing to focus on the biology of mucin (specific types of which are generated by PMP tumors), particularly when it is blocked or down-regulated. Our research is showing that if we block mucin production, we can influence PMP tumor cell growth, and even arrest development of these cells. The development of this knowledge will expand treatments for Pseudomyxoma Peritonei patients.
Related website: http://medschool.creighton.edu/medicine/centers/cancer/res/studies/index.php
Contact person to be notified for patient participation in the program:
Holly Sennett, A.P.R.N.-B.C.
Phone: 402-280-5200
To donate to support Dr Brian W Loggie's appendix cancer research:
make checks payable to “Creighton University” with “PMP Patients Fund” in the ‘memo’ section of the check.
100% of the proceeds will be directed to PMP research.
Inquiries regarding donations may be directed to:
Matt Gerard
Senior Director of Philanthropy
Creighton University
2500 California Plaza
Omaha, NE 68178
P: 402.280.5746 or 800.334.8794
e-mail: mgerard@creighton.edu
Source: Dr Brian W Loggie provided this information to the PMP Pals Network
PMP and HIPEC Research by Dr Brian Loggie
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
Cox II expression in patients with Pseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
Source: Dr Brian Loggie
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
Cox II expression in patients withPseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
Source: Dr Brian Loggie
Gelatinous Ascites:
Articles referring to Dr Brian Loggie's patients
Source: PMP Pals' Network
Brian W. Loggie, MD, CM, FRCSC, FACS
Harold J. Bonnstetter Professor of Surgery
Chief, Division of Surgical Oncology
Creighton University Medical Center
601 N. 30th St, Omaha, NE 68131
Ph: (402) 280-5009 Fax: (402) 280-3448
Assistant to Dr Loggie: Holly Sennett APRN-BC Ph 402-280-4100
PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH, APPENDIX CANCER RESEARCH, DPAM, MESOTHELIOMA
Dr Brian Loggie has created several programs for research in the treatment of PMP and Mesothelioma as follows:
Cox II expression in patients with Pseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
The Cancer Biology program at the Creighton University School of Medicine is directed by Dr. Brian Loggie, professor of surgery, and chief of the division of surgical oncology. He has created a translational working group (TWG) consisting of surgical oncologists, pathologists and basic scientists working collaboratively on several projects relating to Pseudomyxoma Peritonei cure research.
The TWG has begun research identifying mutations in multiple target genes. They are categorizing the mutations on the basis of known signaling pathways in order to combine this knowledge with known pathologic variables and patient outcome. With new biologic insights, it will be possible to consider new approaches to clinical strategies and laboratory testing for PMP patients. The TWG has worked successfully together.
The TWG has previously been successful in identifying novel mutations in the epidermal growth factor (EGFR) gene in Mesothelioma, identifying the biologic implications, confirming the mutation effects on cell signaling function in the laboratory, and devising new treatment strategies.
The TWG seeks to develop information which correlates with prognosis, which aids in developing new treatments, and may guide treatment selection for various presentations and forms of PMP.
The TWG is also continuing to focus on the biology of mucin (specific types of which are generated by PMP tumors), particularly when it is blocked or down-regulated. Our research is showing that if we block mucin production, we can influence PMP tumor cell growth, and even arrest development of these cells. The development of this knowledge will expand treatments for Pseudomyxoma Peritonei patients.
Related website: http://medschool.creighton.edu/medicine/centers/cancer/res/studies/index.php
Contact person to be notified for patient participation in the program:
Holly Sennett, A.P.R.N.-B.C.
Phone: 402-280-5200
To donate to support Dr Brian W Loggie's appendix cancer research:
make checks payable to “Creighton University” with “PMP Patients Fund” in the ‘memo’ section of the check.
100% of the proceeds will be directed to PMP research.
Inquiries regarding donations may be directed to:
Matt Gerard
Senior Director of Philanthropy
Creighton University
2500 California Plaza
Omaha, NE 68178
P: 402.280.5746 or 800.334.8794
e-mail: mgerard@creighton.edu
Source: Dr Brian W Loggie provided this information to the PMP Pals Network
PMP and HIPEC Research by Dr Brian Loggie
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
Cox II expression in patients with Pseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
Source: Dr Brian Loggie
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
Cox II expression in patients withPseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
Source: Dr Brian Loggie
Gelatinous Ascites:
Articles referring to Dr Brian Loggie's patients
Source: PMP Pals' Network
Dr Brian W Loggie describes his cancer research
Copyright © PMP Pals' Network Conference
Dr Andrew M Lowy, Surgeon, UCSD Thornton Hospital, San Diego, CA USA
Read the profile for Dr Andrew M Lowy and contact him directly
Assistant to Dr Andrew M. Lowy: Debbie Soldano RN
Dr Andrew M Lowy
Photo of Dr Andrew M Lowy at PMP Pals' Network Conference
Copyright © PMP Pals’ Network
HIPEC Research Articles by Dr Andrew Lowy
Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality.
Sarnaik AA, Sussman JJ, Ahmad SA, Lowy AM.
Source:Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality.
Sarnaik AA, Sussman JJ, Ahmad SA, Lowy AM.
Source:Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
ASPSM
Dr Andrew M Lowy is a member of the ASPSM
Dr Juan Torres Melero, Surgical Oncologist, Hospital Torrecardenas, Spain
Dr. Juan Torres Melero
Head of the Peritoneal Surface Malignancy Program
Department of Surgery
Hospital Torrecárdenas, Almería. Spain 04009
E-mail: juantorresmelero@gmail.com
Phone: 34-950 016602 Fax: 34 950 016150
Mr Brendan Moran, Pelican Cancer Centre, Basingstoke, United Kingdom
Pelican Cancer Centre Board
Assistant to Mr Brendan Moran, Sue Alves, RN
PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH
Research and Treatment by Prof Brendan Moran MD, FRCS at BNHFT:
Phase II Study Tests Effectiveness of Systemic Chemo for Pseudomyxoma Peritonei
"MicroRNA Profiling of Clinically Different Pseudomyxoma Peritonei Phenotypes"
Donations can be made to:
North Hampshire Medical Trust Fund
National Pseudomyxoma Peritonei Center
Basingstoke and North Hampshire Hospital, NHS Trust Foundation, Basingstoke, UK
Cancer Research UK Center
Southampton General Hospital, Southampton, UK
Source: Christies Hospital, Manchester UK
HIPEC Research Articles by Dr Brendan Moran
CRS and HIPEC for the Treatment of Patients age 30-77 years
Source: North Hampshire Hospital, Basingstoke UK, 2007
Assistant to Mr Brendan Moran, Sue Alves, RN
PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH
Research and Treatment by Prof Brendan Moran MD, FRCS at BNHFT:
Phase II Study Tests Effectiveness of Systemic Chemo for Pseudomyxoma Peritonei
"MicroRNA Profiling of Clinically Different Pseudomyxoma Peritonei Phenotypes"
Donations can be made to:
North Hampshire Medical Trust Fund
National Pseudomyxoma Peritonei Center
Basingstoke and North Hampshire Hospital, NHS Trust Foundation, Basingstoke, UK
Cancer Research UK Center
Southampton General Hospital, Southampton, UK
Source: Christies Hospital, Manchester UK
HIPEC Research Articles by Dr Brendan Moran
CRS and HIPEC for the Treatment of Patients age 30-77 years
Source: North Hampshire Hospital, Basingstoke UK, 2007
Professor David L Morris, Surgical Oncologist, Australia
Professor David L Morris
UNSW Department of Surgery
St George Hospital Kogarah NSW 2217 Australia
Ph 61 2 9113 2070
Fax 61 2 9113 3997
Email david.morris@unsw.edu.au
MESOTHELIOMA and PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH
In vivo model for Pseudomyxoma Peritonei research
Pseudomyxoma Peritonei: investigation of a variety of compounds which appear to be able to dissolve mucin and which may fundamentally alter the management of this condition. These are laboratory and animal studies at present.
Mesothelioma: laboratory and animal research programs are in progress to determine the cause(s) of short and long term outcomes between male and female patients.
Financial contributions can be donated to:
Peritonectomy Foundation (tax deductible in Australia)
For more information, contact:
Professor David L Morris
UNSW Department of Surgery
St George Hospital
Kogarah NSW 2217 Australia
Ph 61 2 9113 2070
Fax 61 2 9113 3997
Email david.morris@unsw.edu.au
Source: Prof David L Morris submitted this information to the PMP Pals’ Network
UNSW Department of Surgery
St George Hospital Kogarah NSW 2217 Australia
Ph 61 2 9113 2070
Fax 61 2 9113 3997
Email david.morris@unsw.edu.au
MESOTHELIOMA and PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH
In vivo model for Pseudomyxoma Peritonei research
Pseudomyxoma Peritonei: investigation of a variety of compounds which appear to be able to dissolve mucin and which may fundamentally alter the management of this condition. These are laboratory and animal studies at present.
Mesothelioma: laboratory and animal research programs are in progress to determine the cause(s) of short and long term outcomes between male and female patients.
Financial contributions can be donated to:
Peritonectomy Foundation (tax deductible in Australia)
For more information, contact:
Professor David L Morris
UNSW Department of Surgery
St George Hospital
Kogarah NSW 2217 Australia
Ph 61 2 9113 2070
Fax 61 2 9113 3997
Email david.morris@unsw.edu.au
Source: Prof David L Morris submitted this information to the PMP Pals’ Network
Appendix Cancer Research by Dr David L Morris
New findings by Dr David L Morris: CRS and Survival of Appendiceal Cancer Patients
Surgical cytoreduction and survival in appendiceal cancer peritoneal carcinomatosis: an evaluation of 46 consecutive patients.
by Chua TC, Al-Alem I, Saxena A, Liauw W, Morris DL.
CONCLUSIONS: Cytoreductive surgery and intraperitoneal chemotherapy may achieve long-term survival in appendiceal malignancies with peritoneal dissemination for which the predictors of outcomes identified through this study may tailor the disease management to commit patients early toward this successful surgical strategy. Source:Ann Surg Oncol. 2011 Jun;18(6):1540-6. Epub 2011 Apr 14.
Radiofrequency Ablation for Treatment of Unresectable Colorectal Pulmonary MetastesRadiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Radiofrequency ablation for colorectal pulmonary metastases represents a step forward towards a nonsurgical option of combining systemic and local treatment for metastatic disease and is a safe treatment with a low risk profile.
Source: David L. Morris, MD, PhD 2009
Morbidity and Mortality: Study of HIPEC and CRS for treatment of peritoneal carcinomatosis
Source Annals of Surgery Feb 2009
DPAM: Peritonectomy Improves Survival
Source Prof David L Morris 2009
Assessment of risk factors following CRS and chemotherapy
Source Prof David L Morris
and Dr Tristan Yan 2009
Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009
Pseudomyxoma Peritonei Long Term Survival (10 year study)
Source: Annals of Surgical Oncology, 2009, Prof David L Morris, St George Hospital,Univ of New South Wales, Sydney, NSW, AU
Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience. This report demonstrates long-term survival outcomes, acceptable perioperative outcomes, and a learning curve associated with the treatment of patients with pseudomyxoma peritonei.
In vivo model for Pseudomyxoma Peritonei researchSource: Prof David L Morris, Sydney Australia, 2009
New findings by Dr David L Morris: CRS and Survival of Appendiceal Cancer Patients
Surgical cytoreduction and survival in appendiceal cancer peritoneal carcinomatosis: an evaluation of 46 consecutive patients.
by Chua TC, Al-Alem I, Saxena A, Liauw W, Morris DL.
CONCLUSIONS: Cytoreductive surgery and intraperitoneal chemotherapy may achieve long-term survival in appendiceal malignancies with peritoneal dissemination for which the predictors of outcomes identified through this study may tailor the disease management to commit patients early toward this successful surgical strategy. Source:Ann Surg Oncol. 2011 Jun;18(6):1540-6. Epub 2011 Apr 14.
Radiofrequency Ablation for Treatment of Unresectable Colorectal Pulmonary MetastesRadiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Radiofrequency ablation for colorectal pulmonary metastases represents a step forward towards a nonsurgical option of combining systemic and local treatment for metastatic disease and is a safe treatment with a low risk profile.
Source: David L. Morris, MD, PhD 2009
Morbidity and Mortality: Study of HIPEC and CRS for treatment of peritoneal carcinomatosis
Source Annals of Surgery Feb 2009
DPAM: Peritonectomy Improves Survival
Source Prof David L Morris 2009
Assessment of risk factors following CRS and chemotherapy
Source Prof David L Morris
and Dr Tristan Yan 2009
Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009
Pseudomyxoma Peritonei Long Term Survival (10 year study)
Source: Annals of Surgical Oncology, 2009, Prof David L Morris, St George Hospital,Univ of New South Wales, Sydney, NSW, AU
Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience. This report demonstrates long-term survival outcomes, acceptable perioperative outcomes, and a learning curve associated with the treatment of patients with pseudomyxoma peritonei.
In vivo model for Pseudomyxoma Peritonei researchSource: Prof David L Morris, Sydney Australia, 2009
ASPSM
Dr David L Morris is a member of the ASPSM
ASPSM
Dr Garrett M Nash is a member of the ASPSM
Peritoneal Surface Malignancy and Pseudomyxoma Peritonei Research Articles by Dr Garrett M Nash
Laparoscopic Surgery for the Treatment of Peritoneal Surface Malignancies including Pseudomyxoma Peritonei
Source: Memorial Sloan Kettering, NY
Peritoneal Surface Malignancy and Pseudomyxoma Peritonei Research Articles by Dr Garrett M Nash
Laparoscopic Surgery for the Treatment of Peritoneal Surface Malignancies including Pseudomyxoma Peritonei
Source: Memorial Sloan Kettering, NY
Dr James F Pingpank, Surgical Oncologist, UPMC Hillman, USA
Read the profile for Dr James F Pingpank and contact him directly
James F. Pingpank, Jr., MD, FACS
Associate Professor of Surgery ,Division of Surgical Oncology
Suite 406, UPMC Cancer Pavillion
5150 Centre Avenue, Pittsburgh, PA 15232
412-692-2852 (Office) 301-325-5733 (Cell)
412-692-2520 (Fax) Email: PingpankJF@UPMC.edu
Peritoneal Carcinomatosis Research by Dr James F Pingpank
Peritoneal Carcinomatois Clinical Trials Study
Source: NIH, Dr James Pingpank, Feb 2009
James F. Pingpank, Jr., MD, FACS
Associate Professor of Surgery ,Division of Surgical Oncology
Suite 406, UPMC Cancer Pavillion
5150 Centre Avenue, Pittsburgh, PA 15232
412-692-2852 (Office) 301-325-5733 (Cell)
412-692-2520 (Fax) Email: PingpankJF@UPMC.edu
Peritoneal Carcinomatosis Research by Dr James F Pingpank
Peritoneal Carcinomatois Clinical Trials Study
Source: NIH, Dr James Pingpank, Feb 2009
Dr Pompiliu Piso, Surgical Oncologist, Regensburg, Germany
Prof. Dr. Pompiliu Piso
Krankenhaus Barmherzige Brüder Regensburg
Prüfeninger Straße 86
93049 Regensburg Germany
Tel: +49 941 369-2201
Email:Pompiliu.Piso@barmherzige-regensburg.de
PHASE I STUDY FOR PERITONEAL CARCINOMATOSIS, HIPEC
Professor Pompiliu Piso provides a prospective, multicenter Phase II study evaluating multimodality treatment with pre- and postoperative systemic chemotherapy with FOLFOX/Cetuximab or FOLFIRI/ Cetuximab, complete cytoreductive surgery (CRS), and HIPEC in patients with diagnosed with Peritoneal Carcinomatosis.
For more information and to contribute to Prof Piso's research, contact:
Prof. Dr. Pompiliu Piso
Leitender Oberarzt
Klinik und Poliklinik für Chirurgie
der Universität Regensburg
Franz Josef Strauß Allee 11
D-93053 Regensburg
Tel.:0941-944-6809
Fax:0941-944-6860
Source: Dr Pompiliu Piso provided this information to the PMP Pals' Network
Peritoneal Carcinomatosis and HIPEC Research by Prof Pompiliu Piso
Krankenhaus Barmherzige Brüder Regensburg
Prüfeninger Straße 86
93049 Regensburg Germany
Tel: +49 941 369-2201
Email:Pompiliu.Piso@barmherzige-regensburg.de
PHASE I STUDY FOR PERITONEAL CARCINOMATOSIS, HIPEC
Professor Pompiliu Piso provides a prospective, multicenter Phase II study evaluating multimodality treatment with pre- and postoperative systemic chemotherapy with FOLFOX/Cetuximab or FOLFIRI/ Cetuximab, complete cytoreductive surgery (CRS), and HIPEC in patients with diagnosed with Peritoneal Carcinomatosis.
For more information and to contribute to Prof Piso's research, contact:
Prof. Dr. Pompiliu Piso
Leitender Oberarzt
Klinik und Poliklinik für Chirurgie
der Universität Regensburg
Franz Josef Strauß Allee 11
D-93053 Regensburg
Tel.:0941-944-6809
Fax:0941-944-6860
Source: Dr Pompiliu Piso provided this information to the PMP Pals' Network
Peritoneal Carcinomatosis and HIPEC Research by Prof Pompiliu Piso
Peritoneal Carcinomatosis Treatment (Study) with Tumor Honing Peptides
Source: Dept of Radiology, Germany 2009
Peritoneal Carcinomatosis Prognosis following treatment with surgery and HIPEC
Source: Prof P Piso, 2009
CRS and HIPEC for the Treatment of Peritoneal Carcinomatosis
Source: Prof Pompiliu Piso, 3rd Annual Symposium, 2008
HIPEC Study with laboratory rats
Source: Deutscher Krebskongress, 2004
ASPSM
Prof Pompiliu Piso is a member of the ASPSM
Dr David C Rice, Surgeon, MDACC, Houston TX, USA
Dr Brigitte Ronnett, Pathologist, Johns Hopkins, USA
DPAM Research by Dr Brigitte M Ronnett
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Dr Armando Sardi, Surgical Oncologist, Mercy Medical Center
Read the profile for Dr Armando Sardi and contact him directly!
Curriculum Vitae for Dr Armando Sardi
Source: Mercy Medical Center
PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH
PERITONEAL CARCINOMATOSIS RESEARCH
Donate to Dr Sardi's research by contacting Sarah Fawcett-Lee
Research by Dr Armando Sardi for the Treatment of Peritoneal Carcinomatosis
Research Focuses on Possible Link Between PMP and Enteric Bacteria (pdf)
Mercy Medical Center (Dr Armando Sardi) researches the possible link between the H Pylori bacteria and mucin production in Pseudomyxoma Peritonei:
Source: Dr Thomas McAvoy and Dr Armando Sardi
Research by Dr Armando Sardi for the Treatment of Peritoneal Carcinomatosis
CRS and HIPEC offer longterm survival for Peritoneal Carcinomatosis of disseminated Appendiceal tumor origin
Source: Dr Armando Sardi, Mercy Med Center, Journal of American College of Surgeons, Sept 2009
Published abstracts by Dr Armando SardiSource: Mercy Medical Center
Curriculum Vitae for Dr Armando Sardi
Source: Mercy Medical Center
PSEUDOMYXOMA PERITONEI PMP CURE RESEARCH
PERITONEAL CARCINOMATOSIS RESEARCH
Donate to Dr Sardi's research by contacting Sarah Fawcett-Lee
Research by Dr Armando Sardi for the Treatment of Peritoneal Carcinomatosis
Research Focuses on Possible Link Between PMP and Enteric Bacteria (pdf)
Mercy Medical Center (Dr Armando Sardi) researches the possible link between the H Pylori bacteria and mucin production in Pseudomyxoma Peritonei:
Source: Dr Thomas McAvoy and Dr Armando Sardi
Research by Dr Armando Sardi for the Treatment of Peritoneal Carcinomatosis
CRS and HIPEC offer longterm survival for Peritoneal Carcinomatosis of disseminated Appendiceal tumor origin
Source: Dr Armando Sardi, Mercy Med Center, Journal of American College of Surgeons, Sept 2009
Published abstracts by Dr Armando SardiSource: Mercy Medical Center
Dr Perry Shen, Surgical Oncologist, Wake Forest University, USA
Read the profile for Dr Perry Shen and contact him directly!
Dr Perry Shen at WFU provides HIPEC
Source: Wake Forest University
APPENDIX CANCER RESEARCH, COLORECTAL, HIPEC, PERITONEAL SURFACE DISEASES
Three trials related to the care of patients diagnosed with Appendix cancers and Peritoneal surface malignancies are being conducted at Wake Forest University. These studies include the following:
1. research into quality of life following the HIPEC procedures.
2. a tumor bank program saving tumor tissue for a variety of research efforts into the molecular events related to peritoneal surface disease.
3. a phase I-II trial evaluating Oxaliplatin in perfusion for patients undergoing HIPEC for Colorectal or Appendix cancer primary carcinomatosis.
Wake Forest University studies mice in the research of Granulocytes to reduce/eliminate tumors
For more information, in general call 336 716 4276, EST.
To schedule appointments or to ask for specific questions regarding research, call Joyce Fenstermaker R.N. at 336 713 3155, EST
ASPSM
Dr Perry Shen is a member of the ASPSM
Wake Forest University Comprehensive Cancer Treatment Center
Dr John H. Stewart IV, Wake Forest University, Appendix Cancer Clinical Trial
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Primary Colorectal Tumors or Tumors of the Appendix
Randomized Phase II Trial to study the side effects and how well giving oxaliplatin or mitomycin C directly into the abdomen, after surgery, works in treating patients with primary colorectal tumors or tumors of the appendix.
For more information, contact:
Principal Investigator: Dr John H. Stewart IV
Contact: Dr John H. Stewart IV
PH: 336-716-9377
EMAIL: jhstewar@wfubmc.edu
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 2715y
or Contact: Joyce Fenstermaker, RN 336-713-3155
Refer to this study by its ClinicalTrials.gov identifier: NCT00904267
Dr John H Stewart IV, Surgical Oncologist, Wake Forest University, USA
Click here to read Dr John H Stewart's profile and to contact him directly
APPENDIX CANCER RESEARCH, COLORECTAL, HIPEC, PERITONEAL SURFACE DISEASES
Three trials related to the care of patients diagnosed with Appendix cancers and Peritoneal surface malignancies are being conducted at Wake Forest University. These studies include the following:
1. research into quality of life following the HIPEC procedures.
2. a tumor bank program saving tumor tissue for a variety of research efforts into the molecular events related to peritoneal surface disease.
3. a phase I-II trial evaluating Oxaliplatin in perfusion for patients undergoing HIPEC for Colorectal or Appendix cancer primary carcinomatosis.
Wake Forest University studies mice in the research of Granulocytes to reduce/eliminate tumors
For more information, in general call 336 716 4276, EST.
To schedule appointments or to ask for specific questions regarding research, call Joyce Fenstermaker R.N. at 336 713 3155, EST
ASPSM
Dr John H Stewart IV is a member of the ASPSM
Dr Paul H Sugarbaker, Washington Hospital Center, Washington DC, USA
Read the profile for Dr Paul H Sugarbaker and contact him directly
GASTROINTESTINAL ONCOLOGY
The Foundation for Applied Research in Gastrointestinal Oncology (FARGO) is a non-profit 501 (c)(3) organization that promotes research, education and patient care in gastrointestinal oncology. FARGO's primary objective is to facilitate the transfer of basic science research into innovations in patient care. The responsibilities of FARGO include financial support, administrative support, and space for continued progress in the prevention and treatment of gastrointestinal cancer.
Donations to FARGO are tax deductible and can be made to:
FARGO
c/o Washington Hospital Center
106 Irving St., NW
Suite 3900
Washington, D.C. 20010
Appendix Cancer Research by Dr Paul H Sugarbaker
Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis from colorectal and appendiceal cancer.
Sugarbaker PH, Van der Speeten K, Anthony Stuart O, Chang D.
Source
Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA.
Abstract
BACKGROUND:
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are a combined treatment modality considered for selected patients with peritoneal carcinomatosis from colorectal and appendiceal cancer. Doxorubicin is a drug consistently used by our group in this clinical setting. The surgical and clinical factors that modify the pharmacokinetics of HIPEC may be important for the design of future perioperative chemotherapy regimens.
MATERIALS AND METHODS:
The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using CRS prior to treatment with HIPEC with doxorubicin as part of a multidrug regimen. The effect of clinical and surgical factors on drug distribution after a single intraperitoneal bolus administration with doxorubicin was determined.
RESULTS:
The pharmacokinetics of 145 patients treated with intraperitoneal doxorubicin showed a 78 times greater exposure to peritoneal surfaces as compared to plasma. At 90 min 12% of the drug remained in the chemotherapy solution and 88% was retained in the body. The extent of visceral resection and peritonectomy increased the clearance of doxorubicin from the peritoneal space. A major resection of visceral peritoneal surface, a contracted peritoneal space, and an incomplete cytoreduction reduced drug clearance.
CONCLUSIONS:
Surgical and clinical factors may require modifications of chemotherapy administration. A large visceral resection and a contracted peritoneal space caused a reduced doxorubicin clearance. Total diffusion surface is an important determinant of doxorubicin pharmacokinetics.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Surgical Responsibilities in the Management of Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, June 2010, Pub Med
Mesenteric Cyst resulting in Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2010
Tailgut Cyst: An Unusual Case of Pseudomyxoma Peritonei
Source: Tumori, Dr Paul H Sugarbaker, 2009
Epithelial appendiceal neoplasms
Source: The Cancer Journal, 2009
Epithelial appendiceal neoplasms: report reviews 900 cases treated at the Washington Hospital Center
Source: Dr Paul H Sugarbaker, Cancer Journal, May 2009
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Management of mucinous urachal neoplasm presenting as Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2008
Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007
Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006
Cytoreductive Surgery (includes graphic illustrations)
Source: Dr Paul H Sugarbaker
Indications for use of CRS and HIPEC
Source: Dr Paul H Sugarbaker
Appendix Cancer Prognosis
Source: Dr Paul H Sugarbaker, Washington Hospital Center
Prognostic indicators for Peritoneal Carcinomatosis originating with gastrointestinal adenocarcinoma
Source: Dr Paul H Sugarbaker, 2005
Atlas of Appendix Cancer (includes graphic illustrations)
Source: Dr Paul H Sugarbaker
Articles referring to Dr Paul Sugarbaker and his patients
Source: PMP Pals' Network
Dr Paul H Sugarbaker Reports on the Effects of Doxorubicin for Appendix Cancer Treatment
Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis from colorectal and appendix cancer.
Sugarbaker PH, Van der Speeten K, Anthony Stuart O, Chang D.
Source: Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA.
Abstract
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are a combined treatment modalityperitoneal carcinomatosis from colorectal and appendiceal cancer. Doxorubicin is a drug consistently used by our group in this clinical setting. The surgical and clinical factors that modify the pharmacokinetics of HIPEC may be important for the design of future perioperative chemotherapy regimens.
MATERIALS AND METHODS: The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using CRS prior to treatment with HIPEC with doxorubicin as part of a multidrug regimen. The effect of clinical and surgical factors on drug distribution after a single intraperitoneal bolus administration with doxorubicin was determined.
RESULTS: The pharmacokinetics of 145 patients treated with intraperitoneal doxorubicin showed a 78 times greater exposure to peritoneal surfaces as compared to plasma. At 90 min 12% of the drug remained in the chemotherapy solution and 88% was retained in the body. The extent of visceral resection and peritonectomy increased the clearance of doxorubicin from the peritoneal space. A major resection of visceral peritoneal surface, a contracted peritoneal space, and an incomplete cytoreduction reduced drug clearance.
CONCLUSIONS: Surgical and clinical factors may require modifications of chemotherapy administration. A large visceral resection and a contracted peritoneal space caused a reduced doxorubicin clearance. Total diffusion surface is an important determinant of doxorubicin pharmacokinetics.
Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis from colorectal and appendix cancer.
Sugarbaker PH, Van der Speeten K, Anthony Stuart O, Chang D.
Source: Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA.
Abstract
BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are a combined treatment modalityperitoneal carcinomatosis from colorectal and appendiceal cancer. Doxorubicin is a drug consistently used by our group in this clinical setting. The surgical and clinical factors that modify the pharmacokinetics of HIPEC may be important for the design of future perioperative chemotherapy regimens.
MATERIALS AND METHODS: The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using CRS prior to treatment with HIPEC with doxorubicin as part of a multidrug regimen. The effect of clinical and surgical factors on drug distribution after a single intraperitoneal bolus administration with doxorubicin was determined.
RESULTS: The pharmacokinetics of 145 patients treated with intraperitoneal doxorubicin showed a 78 times greater exposure to peritoneal surfaces as compared to plasma. At 90 min 12% of the drug remained in the chemotherapy solution and 88% was retained in the body. The extent of visceral resection and peritonectomy increased the clearance of doxorubicin from the peritoneal space. A major resection of visceral peritoneal surface, a contracted peritoneal space, and an incomplete cytoreduction reduced drug clearance.
CONCLUSIONS: Surgical and clinical factors may require modifications of chemotherapy administration. A large visceral resection and a contracted peritoneal space caused a reduced doxorubicin clearance. Total diffusion surface is an important determinant of doxorubicin pharmacokinetics.
ASPSM
Dr Paul H Sugarbaker is a member of the ASPSM
Dr Walley Temple, Surgeon, Canada
Click here to read Dr Temple's profile and to contact him directly!
PHASE II STUDY FOR PERITONEAL CARCINOMATOSIS
Source: Dr Walley Temple, University of Calgary
Dr Atonios-Apostolos K Tentes, Surgeon,Didimotichon, Greece
Dr Atonios-Apostolos K Tentes
Didimotichon General Hospital
Didimotichon, 68300, Greece
Email atentes@did-hosp.gr
GASTRIC CANCER, COLORECTAL CANCER, OVARIAN CANCER, PANCREATIC CANCER
Antonios-Apostolos K Tentes, M.D.Director of the Surgical Department at the Didimotichon General Hospital in Didmotichon Greece, is conducting several clinical trials, as described below:
Colorectal Cancer: This study focuses on patients with colorectal cancer who have T3 and T4 tumors. The patients are randomly selected to undergo either surgery alone, or surgery combined with IPHC, provided that R0 resection has been performed. The final goal of the study is compare the survival rates between these two groups of patients.
Gastric Cancer: This study includes patients with T3 and T4 tumors. The patients undergo D2 gastrectomies and receive HIPEC. No further treatment is required. The goal of this study is to identify the survival and recurrence rates.
Gastrointestinal Cancer without Peritoneal Carcinomatosis: HIPEC as an adjuvant in locally advanced cancer.
Pancreatic Cancer: Study the effect of heated intraperitoneal gemcitabine after potentially curative resection of pancreatic cancer without peritoneal dissemination. This study seeks 15 more patients , to be monitored for 3 years, to study if the rate of locoregional recurrences is decreased and the overall survival is increased.
Ovarian Cancer with Peritoneal Dissemination. Study of the effect of maximal cytoreductive surgery (CRS) combined with HIPEC.
For more information, contact:
Dr Atonios-Apostolos K Tentes
Didimotichon General Hospital
Didimotichon, 68300, Greece
Email atentes@did-hosp.gr
Source: Dr Atonios- Apostolos Tentes provided this information to the PMP Pals' Network
Dr Herbert J Zeh, Surgeon, UPMC Hillman Cancer Center, Pgh, PA, USA
Read the profile for Dr Herbert J Zeh and contact him directly for a consultation
Herbert J. Zeh, III, MD
Assistant Professor of Surgery
Division of Surgical Oncology
University of Pittsburgh
Pittsburgh, PA, USA
Peritoneal Carcinomatosis Research by Dr Herbert J Zeh III
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Pseudomyxoma Peritonei Research by Dr Herbert J Zeh III
Dr Zeh's special interest studies:Identification of molecular targets in Pseudomyxoma Peritonei via clonal analyses of metastases.
Herbert J. Zeh, III, MD
Assistant Professor of Surgery
Division of Surgical Oncology
University of Pittsburgh
Pittsburgh, PA, USA
Peritoneal Carcinomatosis Research by Dr Herbert J Zeh III
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Pseudomyxoma Peritonei Research by Dr Herbert J Zeh III
Dr Zeh's special interest studies:Identification of molecular targets in Pseudomyxoma Peritonei via clonal analyses of metastases.
This article generates from Italy and focuses on a 60 year old female, whose case was originally thought to have originated from the ovary, actually originated with the appendix.
Appendiceal mucocele. A case report and literature review.
Researchers: Caracappa D, Gullà N, Gentile D, Listorti C, Boselli C, Cirocchi R, Bellezza G, Noya G.
Source: Dipartimento di Scienze Chirurgiche S.C di Chirurgia Generale ed Oncologica, Università degli Studi di Perugia, Italia. Ann Ital Chir. 2011 May-Jun;82(3):239-45.
Abstract: Appendiceal mucocele is a rare disease (0.3% of all appendectomy) and is characterized by the accumulation of mucoid material in the appendiceal lumen. Etiopathogenesis can be inflammatory or neoplastic. Four entities can be distinguished on the basis of histopathologic epithelial characteristics:
simple appendiceal mucocele (AM),
mucocele with epithelial hyperplasia,
cystadenoma and
cystadenocarcinoma; the last two subgroups represent neoplastic forms.
Dissemination of neoplastic cells and mucoid material in abdominal cavity, caused by appendiceal perforation, clinically results in pseudomyxoma peritonei which is the dramatic evolution in 10-15% of cases.
Clinically it can remain either asymptomatic for long time or it can manifest with abdominal pain that can be associated with the presence of a palpable mass. The most common clinical manifestation is pain in the right iliac fossa.
Preoperative diagnosis is rare, while it is more frequently intraoperative.
Therapy is fundamentally surgical: appendectomy is curative for simple AM,
for AM with epithelial hyperplasia and for cystadenoma with intact appendiceal base;
cecum resection is indicated for cystadenoma with larger base of implantation;
right hemicolectomy has been the elective treatment in case of cystadenocarcinoma for several years although Gonzalez-Moreno(Spain) and Sugarbaker (USA) have recently demonstrated its validity as definitive treatment only if it is performed in order to obtain complete cytoreduction, if there is lymph node involvement, or if histopathological examination indicates non-mucinous type.
We report the case of a 60-year-old woman that presented with cystic neoformation in the right iliac fossa, that was preoperatively considered deriving from the ovary. We intraoperatively found the presence of appendiceal mucocele that histological examination defined as mucinous cystadenoma.
PMID:21780569
Researchers: Caracappa D, Gullà N, Gentile D, Listorti C, Boselli C, Cirocchi R, Bellezza G, Noya G.
Source: Dipartimento di Scienze Chirurgiche S.C di Chirurgia Generale ed Oncologica, Università degli Studi di Perugia, Italia. Ann Ital Chir. 2011 May-Jun;82(3):239-45.
Abstract: Appendiceal mucocele is a rare disease (0.3% of all appendectomy) and is characterized by the accumulation of mucoid material in the appendiceal lumen. Etiopathogenesis can be inflammatory or neoplastic. Four entities can be distinguished on the basis of histopathologic epithelial characteristics:
simple appendiceal mucocele (AM),
mucocele with epithelial hyperplasia,
cystadenoma and
cystadenocarcinoma; the last two subgroups represent neoplastic forms.
Dissemination of neoplastic cells and mucoid material in abdominal cavity, caused by appendiceal perforation, clinically results in pseudomyxoma peritonei which is the dramatic evolution in 10-15% of cases.
Clinically it can remain either asymptomatic for long time or it can manifest with abdominal pain that can be associated with the presence of a palpable mass. The most common clinical manifestation is pain in the right iliac fossa.
Preoperative diagnosis is rare, while it is more frequently intraoperative.
Therapy is fundamentally surgical: appendectomy is curative for simple AM,
for AM with epithelial hyperplasia and for cystadenoma with intact appendiceal base;
cecum resection is indicated for cystadenoma with larger base of implantation;
right hemicolectomy has been the elective treatment in case of cystadenocarcinoma for several years although Gonzalez-Moreno(Spain) and Sugarbaker (USA) have recently demonstrated its validity as definitive treatment only if it is performed in order to obtain complete cytoreduction, if there is lymph node involvement, or if histopathological examination indicates non-mucinous type.
We report the case of a 60-year-old woman that presented with cystic neoformation in the right iliac fossa, that was preoperatively considered deriving from the ovary. We intraoperatively found the presence of appendiceal mucocele that histological examination defined as mucinous cystadenoma.
PMID:21780569
Employment Opportunities in Research
Federal Agencies and Cancer Research Programs
While the National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training, cancer research is also supported through a number of other federal agencies and institutes. On this page you will find links and information to agencies that carry out vital cancer research programs.
NATIONAL INSTITUTES OF HEALTH (NIH)
The NIH, an institute of the U.S. Department of Health and Human Services (HHS), is the primary federal agency for conducting and supporting medical research. It is composed of 27 Institutes and Centers, including the National Cancer Institute (NCI), and provides leadership and financial support to researchers in every state across the U.S. and throughout the world.
Website: http://www.nih.gov/
Director: Francis Collins, M.D., Ph.D.
NATIONAL CANCER INSTITUTE (NCI)
The NCI, an institute of the National Institutes of Health (NIH), is the federal government's principal agency for cancer research and training.
Website: http://www.cancer.gov/
Director: Harold E. Varmus, M.D.
NCI Links:
AHRQ, an agency of the National Institutes of Health (NIH), conducts and supports health services research, both within AHRQ as well as in leading academic institutions, hospitals, physicians' offices, health care systems, and many other settings across the country. The Agency has a broad research portfolio that touches on nearly every aspect of health care.
Website: http://www.ahrq.gov/
Director: Carolyn M. Clancy, M.D.
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
The CDC, an institute of the U.S. Department of Health and Human Services (HHS), works to protect public health and safety by providing information to enhance health decisions, and promoting health through partnerships with state health departments and other organizations.
Website: http://www.cdc.gov/
Director: Thomas R. Frieden, M.D., M.P.H.
CDC Cancer Programs:
The FDA, an agency of the U.S. Department of Health and Human Services (HHS), is responsible for protecting the public health by assuring the safety, efficacy and security of human and veterinary drugs, biological products, medical devices, our nation's food supply, cosmetics and products that emit radiation. The agency plays a vital role in researching the products of cutting edge science that are central to the treatment and prevention of cancer.
Website: http://www.fda.gov/
Commissioner: Margaret Hamburg, M.D.
FDA Cancer Programs:
HRSA, an agency of the HHS, is the primary Federal agency for improving access to health care services for the medically underserved. HRSA oversees a range of programs and initiatives, including the national system that allocates organs, tissue, and blood stem cells for transplant as well as programs designed to enhance the diversity and distribution of the health care workforce.
Website: http://www.hrsa.gov/
Administrator: Mary Wakefield, Ph.D., R.N.
DEPARTMENT OF ENERGY (DOE)
The DOE is a Cabinet-level department which promotes scientific and technological innovation in support of its mission to advance the nation's energy security. The DOE Office of Biological and Environmental Research manages the Low-Dose Radiation Research Program which supports research that will help determine health risks from exposures to low levels of radiation.
Website: http://www.doe.gov/
Secretary: Steven Chu, Ph.D.
DOE Cancer Program:
Source: AACR
While the National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training, cancer research is also supported through a number of other federal agencies and institutes. On this page you will find links and information to agencies that carry out vital cancer research programs.
NATIONAL INSTITUTES OF HEALTH (NIH)
The NIH, an institute of the U.S. Department of Health and Human Services (HHS), is the primary federal agency for conducting and supporting medical research. It is composed of 27 Institutes and Centers, including the National Cancer Institute (NCI), and provides leadership and financial support to researchers in every state across the U.S. and throughout the world.
Website: http://www.nih.gov/
Director: Francis Collins, M.D., Ph.D.
NATIONAL CANCER INSTITUTE (NCI)
The NCI, an institute of the National Institutes of Health (NIH), is the federal government's principal agency for cancer research and training.
Website: http://www.cancer.gov/
Director: Harold E. Varmus, M.D.
NCI Links:
- National Cancer Advisory Board (NCAB): NCAB is an advisory board to the Secretary of the Department of Health and Human Services (HHS) and the NCI Director with respect to NCI activities.
AHRQ, an agency of the National Institutes of Health (NIH), conducts and supports health services research, both within AHRQ as well as in leading academic institutions, hospitals, physicians' offices, health care systems, and many other settings across the country. The Agency has a broad research portfolio that touches on nearly every aspect of health care.
Website: http://www.ahrq.gov/
Director: Carolyn M. Clancy, M.D.
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
The CDC, an institute of the U.S. Department of Health and Human Services (HHS), works to protect public health and safety by providing information to enhance health decisions, and promoting health through partnerships with state health departments and other organizations.
Website: http://www.cdc.gov/
Director: Thomas R. Frieden, M.D., M.P.H.
CDC Cancer Programs:
- National Breast & Cervical Cancer Early Detection Program (NBCCEDP)
- National Comprehensive Cancer Control Program (NCCCP)
- National Program of Cancer Registries (NPCR)
- National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP)
- Comprehensive Cancer Control Initiative
- National Cancer Registries Program
- Colorectal Cancer Screening, Education and Outreach
- Skin Cancer Prevention Programs
- Prostate Cancer Awareness Campaign
- Ovarian Cancer Awareness
- Geraldine Ferraro Blood Cancer Program
The FDA, an agency of the U.S. Department of Health and Human Services (HHS), is responsible for protecting the public health by assuring the safety, efficacy and security of human and veterinary drugs, biological products, medical devices, our nation's food supply, cosmetics and products that emit radiation. The agency plays a vital role in researching the products of cutting edge science that are central to the treatment and prevention of cancer.
Website: http://www.fda.gov/
Commissioner: Margaret Hamburg, M.D.
FDA Cancer Programs:
- Center for Drug Evaluation and Research (CDER)
- Cancer Drug Development Patient Consultant Program
- Office of Oncology Drug Products
HRSA, an agency of the HHS, is the primary Federal agency for improving access to health care services for the medically underserved. HRSA oversees a range of programs and initiatives, including the national system that allocates organs, tissue, and blood stem cells for transplant as well as programs designed to enhance the diversity and distribution of the health care workforce.
Website: http://www.hrsa.gov/
Administrator: Mary Wakefield, Ph.D., R.N.
DEPARTMENT OF ENERGY (DOE)
The DOE is a Cabinet-level department which promotes scientific and technological innovation in support of its mission to advance the nation's energy security. The DOE Office of Biological and Environmental Research manages the Low-Dose Radiation Research Program which supports research that will help determine health risks from exposures to low levels of radiation.
Website: http://www.doe.gov/
Secretary: Steven Chu, Ph.D.
DOE Cancer Program:
Source: AACR
NIH Research Grant Opportunities
NIH Announces New Genome Project to Target Research for Rare Diseases
Source: NIH
NIH Programs to Study Rare Diseases
Source: NIH
US Congress Approves $24 Million to Study Rare Diseases Including Pseudomyxoma Peritonei
Source: Reuters
National Institutes of Health (NIH) Research Plans for Digestive Diseases
Source: NIH
Peritoneal Carcinomatois Clinical Trials Study
Source: NIH, Dr James Pingpank, Feb 2009
Peritoneal Carcinomatosis Trial
Source: NCI/NIH Dr James Pinkpank, April 2007
Phase I Study for Patients with Peritoneal Carcinomatosis
Source: NIH
National Cancer Institute/National Institutes of Health (NCI/NIH) Database of Clinical Trials
NIH Announces New Research Funding ($120 Million) for Rare Diseases, including Pseudomyxoma Peritonei
Source: Top News
Cancer Cure Research Grant Opportunities, USA
Federal Cancer Research Opportunities
Source: AACR
Foundation for Digestive Health and Nutrition: $3 Million for Research Grants
Source: Foundation for Digestive Health
Foundation for Digestive Health Funds Gastric Cancer Risk/Helicobacter Pylori Research
Source: Foundation for Digestive Health
NIH Research Grants
NIH Office of Rare Disorders
Source: NIH
American Association of Cancer Research Funding Opportunities
Source: AACR
ASCO Research Grants
NORD Research Grant Programs
Source: NORD
NCCN Oncology Research Grant Program
Source: NCCN
Comparative Effectiveness Research Plan in the US
Source: AACR
Foundation for Digestive Health and Nutrition: $3 Million for Research Grants
Source: Foundation for Digestive Health
Foundation for Digestive Health Funds Gastric Cancer Risk/Helicobacter Pylori Research
Source: Foundation for Digestive Health
NIH Research Grants
NIH Office of Rare Disorders
Source: NIH
American Association of Cancer Research Funding Opportunities
Source: AACR
ASCO Research Grants
NORD Research Grant Programs
Source: NORD
NCCN Oncology Research Grant Program
Source: NCCN
Comparative Effectiveness Research Plan in the US
Cancer Cure Research Grant Opportunities, International
American Society of Peritoneal Treatment Malignancies
Appendix Cancer and Pseudomyxoma Peritonei Patients
As a volunteer patient advocacy program, representing the needs of patients and their families, we neither solicit, nor receive funding or advertising revenue from cancer treatment centers, pharmaceutical companies, or physicians who treat cancer.
We support our program services through subscription dues, gifts from fellow patients and their families, and the hours of time and talents that we share to serve others!
This web page is sponsored by Bob and Misty, USA
Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Individuals or organizations who plagiarize this copyrighted website will be prosecuted.
Copyright 2012 by PMP Pals' Network/All rights reserved. Updated 01.19.12
